Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

INCORVAIA, Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.257
EU - Europa 5.952
AS - Asia 5.317
Continente sconosciuto - Info sul continente non disponibili 895
SA - Sud America 850
AF - Africa 168
OC - Oceania 13
Totale 23.452
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.979
SG - Singapore 2.096
RU - Federazione Russa 1.813
IT - Italia 1.481
CN - Cina 1.159
BR - Brasile 694
DE - Germania 586
HK - Hong Kong 511
VN - Vietnam 484
FI - Finlandia 426
PL - Polonia 390
BD - Bangladesh 271
FR - Francia 268
GB - Regno Unito 255
JP - Giappone 195
UA - Ucraina 154
CA - Canada 147
IN - India 133
IE - Irlanda 131
NL - Olanda 101
KR - Corea 88
SE - Svezia 81
IQ - Iraq 73
MX - Messico 61
AR - Argentina 52
TR - Turchia 51
RO - Romania 47
AT - Austria 46
ES - Italia 45
ZA - Sudafrica 43
BE - Belgio 35
MA - Marocco 28
EC - Ecuador 26
IR - Iran 23
UZ - Uzbekistan 23
ID - Indonesia 21
JM - Giamaica 21
PK - Pakistan 21
AE - Emirati Arabi Uniti 20
MY - Malesia 20
CI - Costa d'Avorio 19
NP - Nepal 18
EG - Egitto 17
VE - Venezuela 17
CL - Cile 15
KE - Kenya 15
CO - Colombia 14
SA - Arabia Saudita 14
PH - Filippine 13
AU - Australia 12
BG - Bulgaria 12
CZ - Repubblica Ceca 12
LT - Lituania 11
PY - Paraguay 11
CH - Svizzera 10
TN - Tunisia 10
UY - Uruguay 10
TW - Taiwan 9
CR - Costa Rica 8
KZ - Kazakistan 8
NI - Nicaragua 8
PS - Palestinian Territory 8
AZ - Azerbaigian 7
LB - Libano 7
PT - Portogallo 7
AL - Albania 6
DZ - Algeria 6
JO - Giordania 6
TT - Trinidad e Tobago 6
BH - Bahrain 5
BO - Bolivia 5
GR - Grecia 5
NO - Norvegia 5
PA - Panama 5
PE - Perù 5
CY - Cipro 4
DO - Repubblica Dominicana 4
ME - Montenegro 4
SN - Senegal 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
BY - Bielorussia 3
DK - Danimarca 3
ET - Etiopia 3
EU - Europa 3
GD - Grenada 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
IL - Israele 3
KG - Kirghizistan 3
LV - Lettonia 3
MD - Moldavia 3
MM - Myanmar 3
NG - Nigeria 3
RS - Serbia 3
TH - Thailandia 3
BW - Botswana 2
GH - Ghana 2
Totale 22.524
Salva come PNG Salva come JPEG
Città #
Ashburn 1.376
Singapore 1.303
Fairfield 826
San Jose 816
Chandler 578
Hong Kong 477
Houston 440
Woodbridge 424
Moscow 343
Wilmington 329
Palermo 327
Seattle 319
Zgierz 305
Ann Arbor 278
Cambridge 258
Los Angeles 231
Council Bluffs 223
New York 203
Beijing 194
Dallas 194
Helsinki 194
Tokyo 185
Ho Chi Minh City 166
Rome 165
Hefei 156
The Dalles 154
Lauterbourg 147
Medford 133
Dublin 126
Santa Clara 124
Frankfurt am Main 111
Boardman 108
Hanoi 108
Munich 102
Des Moines 94
Chicago 90
Milan 90
Altamura 89
Princeton 88
Buffalo 85
Jacksonville 75
San Diego 75
Ludwigshafen am Rhein 72
Lawrence 71
São Paulo 62
London 58
Orem 55
Nanjing 51
Seoul 50
Lappeenranta 49
Denver 44
Warsaw 44
Nuremberg 42
Toronto 42
Atlanta 39
Montreal 39
Kitzingen 37
Brussels 35
Phoenix 35
Bremen 34
Dearborn 33
Johannesburg 33
Jinan 31
Brooklyn 30
Redondo Beach 30
Amsterdam 28
Changsha 28
Naples 28
Chennai 27
Stockholm 27
Tulsa 27
Haiphong 26
Guangzhou 24
Rio de Janeiro 23
Poplar 22
Baghdad 21
Turin 21
Mexico City 20
Abidjan 19
Boston 19
Tianjin 19
San Francisco 18
Schiffdorf 18
Tashkent 18
Vienna 18
Bari 17
Columbus 17
Erbil 17
Manchester 17
Shanghai 17
Shenyang 17
Turku 17
Memphis 16
Pune 16
Salt Lake City 16
Tampa 16
Falls Church 15
Hải Dương 15
Nanchang 15
Washington 15
Totale 13.819
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 357
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 351
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 329
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 320
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 309
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 307
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 307
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 283
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 277
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 277
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 271
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 265
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 263
Liquid Biopsy in Breast Cancer 255
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 253
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 242
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 238
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 233
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 232
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 230
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 228
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 224
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 223
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 222
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma 221
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 218
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 212
Serum follistatin in patients with prostate cancer metastatic to the bone 211
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 211
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 208
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 204
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 202
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 202
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 200
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 199
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 195
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 190
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 190
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 190
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 189
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 185
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 183
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 182
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 181
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 180
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 180
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 178
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 178
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 177
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 177
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 174
Liquid Biopsy in Gynecological Cancers 174
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 173
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 171
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 170
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 169
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 167
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 164
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 162
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 159
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 157
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 157
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women 155
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 151
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 150
Liquid Biopsy in Gastrointestinal Stromal Tumor 149
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 148
Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature 148
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 147
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 147
Recent advances in desmoid tumor therapy 146
Cancer of the Thyroid 146
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 145
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 143
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 143
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 143
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 142
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 141
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 140
Molecular tumor board 139
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 139
I tumori stromali gastrointestinali: dalla biologia alla clinica 136
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon 136
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography 136
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 135
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 134
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 133
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 133
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report 131
Current clinically validated applications of liquid biopsy 130
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 130
Scientific Communication and oncology – "The bridge between knowledge and patients" 124
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 123
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 123
Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices 122
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 121
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 120
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 118
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 117
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 116
Totale 18.716
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.177 0 186 59 28 53 70 55 69 113 162 166 216
2022/20231.686 170 306 37 217 160 245 91 143 169 33 75 40
2023/20241.184 43 127 104 112 76 181 145 122 24 65 21 164
2024/20253.414 117 153 140 267 151 232 417 283 243 410 417 584
2025/202611.075 854 332 770 981 1.196 1.586 1.512 1.015 860 814 601 554
2026/2027696 545 151 0 0 0 0 0 0 0 0 0 0
Totale 23.452